The National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring the development of a new vaccine to protect against WNV. A human clinical trial is underway. The vaccine uses a new hydrogen peroxide-based process to inactivate the virus. Because it is inactive, it can be given to immunocompromised and elderly persons.
